Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
81 participants
INTERVENTIONAL
2008-10-13
2009-07-24
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
2% CP-690,550 QD
CP-690,550
Topical treatment once daily for 28 days
0.2% CP-690,550 QD
CP-690,550
Topical treatment once daily for 28 days
0.02% CP-690,550 QD
CP-690,550
Topical treatment once daily for 28 days
2% CP-690,550 BID
CP-690,550
Topical treatment twice daily for 28 days
0.2% CP-690,550 BID
CP-690,550
Topical treatment twice daily for 28 days
0.02% CP-690,550 BID
CP-690,550
Topical treatment twice daily for 28 days
Placebo Vehicle QD
Placebo Vehicle
Topical treatment once daily for 28 days
Placebo Vehicle BID
Placebo Vehicle
Topical treatment twice daily for 28 days
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
CP-690,550
Topical treatment once daily for 28 days
CP-690,550
Topical treatment once daily for 28 days
CP-690,550
Topical treatment once daily for 28 days
CP-690,550
Topical treatment twice daily for 28 days
CP-690,550
Topical treatment twice daily for 28 days
CP-690,550
Topical treatment twice daily for 28 days
Placebo Vehicle
Topical treatment once daily for 28 days
Placebo Vehicle
Topical treatment twice daily for 28 days
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Able to withdraw all prior psoriasis treatments
* Must agree to avoid prolonged exposure to the sun and avoid use of tanning booths or other ultraviolet light sources during the study
Exclusion Criteria
* Pregnant or lactating women
* Unwilling to use appropriate contraceptive methods
18 Years
65 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Pfizer
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Pfizer CT.gov Call Center
Role: STUDY_DIRECTOR
Pfizer
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of California Irvine
Irvine, California, United States
Therapeutics Clinical Research
San Diego, California, United States
RUSH University Medical Center
Chicago, Illinois, United States
Tufts Medical Center
Boston, Massachusetts, United States
University of Michigan
Ann Arbor, Michigan, United States
Minnesota Clinical Study Center
Fridley, Minnesota, United States
Central Dermatology, PC
St Louis, Missouri, United States
Dermatology Consulting Services
High Point, North Carolina, United States
The Imaging Center
High Point, North Carolina, United States
Wake Forest University Health Sciences
Winston-Salem, North Carolina, United States
Oregon Medical Research Center, PC
Portland, Oregon, United States
Oregon Health & Science University
Portland, Oregon, United States
DermResearch, Inc.
Austin, Texas, United States
University of Utah School of Medicine
Salt Lake City, Utah, United States
Guildford Dermatology Specialists
Surrey, British Columbia, Canada
NewLab Clinical Research Inc.
St. John's, Newfoundland and Labrador, Canada
K.Papp Clinical Research Inc.
Waterloo, Ontario, Canada
Innovaderm Research, Inc.
Montreal, Quebec, Canada
Siena Medical Research
Montreal, Quebec, Canada
Centre de Recherche Dermatologique du Quebec metropolitain
Québec, Quebec, Canada
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Ports WC, Feldman SR, Gupta P, Tan H, Johnson TR, Bissonnette R. Randomized Pilot Clinical Trial of Tofacitinib Solution for Plaque Psoriasis: Challenges of the Intra-Subject Study Design. J Drugs Dermatol. 2015 Aug;14(8):777-84.
Related Links
Access external resources that provide additional context or updates about the study.
To obtain contact information for a study center near you, click here.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
A3921038
Identifier Type: -
Identifier Source: org_study_id